NCT07192991 Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
| NCT ID | NCT07192991 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Latin American Cooperative Oncology Group |
| Condition | Neuroendocrine Carcinomas |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-12-16 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-12-16 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.
Eligibility Criteria
Inclusion Criteria: * ≥18 years old * Diagnosed between August 2014 and August 2024 with one of the following: * Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) * Large-cell neuroendocrine carcinoma (LCNEC) or mixed * Small Cell Lung Cancer (SCLC) or mixed * Adequate and accessible medical records for data collection * Tumor block collected from 2014 onwards Exclusion Criteria: * Patients with active, concurrent malignancies at the time of NEC diagnosis, except for non-invasive cancers like basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer. * Patients or their legal representatives unwilling or unable to provide informed consent (if needed per ethics committee).
Contact & Investigator
Rachel Simões Pimenta Riechelmann
PRINCIPAL INVESTIGATOR
Latin American Cooperative Oncology Group
Frequently Asked Questions
Who can join the NCT07192991 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neuroendocrine Carcinomas. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07192991 currently recruiting?
Yes, NCT07192991 is actively recruiting participants. Contact the research team at lacog1324@lacog.group for enrollment information.
Where is the NCT07192991 trial being conducted?
This trial is being conducted at Buenos Aires, Argentina, Buenos Aires, Argentina, Buenos Aires, Argentina, Cachoeiro de Itapemirim, Brazil and 11 additional locations.
Who is sponsoring the NCT07192991 clinical trial?
NCT07192991 is sponsored by Latin American Cooperative Oncology Group. The principal investigator is Rachel Simões Pimenta Riechelmann at Latin American Cooperative Oncology Group. The trial plans to enroll 200 participants.